Pulsenmore Ltd. (PLSM)
| Market Cap | 27.58M -38.5% |
| Revenue (ttm) | 12.55M +314.3% |
| Net Income | -4.97M |
| EPS | -0.77 |
| Shares Out | 6.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,140 |
| Open | 4.550 |
| Previous Close | 4.000 |
| Day's Range | 3.950 - 4.550 |
| 52-Week Range | 3.000 - 10.280 |
| Beta | 0.29 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 30, 2026 |
About PLSM
Pulsenmore Ltd., a medical device company, engages in the research, development, manufacture, marketing, and sale of portable ultrasound solutions. The company provides Pulsenmore ES and Pulsenmore FC products. The company was incorporated in 2014 and is based in Omer, Israel.
Financial Performance
In 2025, Pulsenmore's revenue was 40.02 million, an increase of 314.28% compared to the previous year's 9.66 million. Losses were -15.85 million, -56.85% less than in 2024.
Financial numbers in ILS Financial StatementsNews
Pulsenmore Announces Full Year 2025 Financial Results and Webcast
Management to Host Conference Call and Webcast today at 8:30am ET to Discuss Results and Provide Business Update OMER, Israel, March 30, 2026 /PRNewswire/ – Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM...
Pulsenmore Announces Full Year 2025 Earnings Conference Call
OMER, Israel, March 25, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced that it will release its financial results for full y...
Pulsenmore Ltd. Ordinary Shares trading resumes
09:39 EST Pulsenmore (PLSM)Ltd. Ordinary Shares trading resumes
Pulsenmore Ltd. Ordinary Shares trading halted, volatility trading pause
09:34 EST Pulsenmore (PLSM)Ltd. Ordinary Shares trading halted, volatility trading pause
Pulsenmore announces commercial engagement with TLC Perinatal PA
Pulsenmore (PLSM)announced a new commercial engagement with TLC Perinatal PA, a maternal-fetal medicine and women’s ultrasound practice in Maryland, as part of its growing U.S. rollout. In early Febru...
Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance
OMER, Israel, Feb. 9, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced a new commercial engagement with TLC Perinatal PA, a ma...
Pulsenmore announces first commercial engagement with medical center in the U.S.
Pulsenmore (PLSM)announced a first commercial engagement with a medical center in the U.S., following receipt of FDA approval for its home pregnancy ultrasound product. At the end of January 2026,
Pulsenmore Announces First Commercial Engagement with a Leading U.S.-Based Medical Center
OMER, Israel, Feb. 2, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced a first commercial engagement with a medical center in ...
Pulsenmore and Clalit Health Services Launch First At-Home Follicular Monitoring Service for IVF and Fertility Preservation
Commercial agreement potentially valued at approximately $4.5 million over five years following 18 month pilot; Service to be deployed via Beilinson NEXT, Beilinson's virtual hospital RAMAT GAN, Israe...
Pulsenmore to commence trading on Nasdaq
Pulsenmore (PLSM)announced that its shares will begin trading on Nasdaq at the U.S. market open on January 21. The company’s shares will trade under the ticker symbol “PLSM” on the
Pulsenmore To Commence Trading on Nasdaq as It Expands FDA-authorized Home Prenatal Ultrasound Devices in the U.S.
RAMAT GAN, Israel, Jan. 21, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced that its shares will begin trading on Nasdaq at ...